Secondary anti‐viral prophylaxis in solid organ transplant recipients for the prevention of cytomegalovirus relapse: A systematic review and meta‐analysis
Transplant Infectious Disease · 2024
DOI: 10.1111/tid.14393 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Transplant Infectious Disease, 2024. Verfasst von David Moynan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Mater Misericordiae University Hospital, Dublin, Ireland. Hauptthemen laut MEDLINE: Antiviral Agents, Cytomegalovirus Infections, Organ Transplantation, Secondary Prevention. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Infectious Disease Society of Ireland.
Abstract (Originalsprache)
Background
Cytomegalovirus (CMV) is a significant cause of morbidity and mortality in solid organ transplant recipients (SOTRs). Secondary prophylaxis (SP) is not routinely recommended by guidelines on the management of CMV in SOTR but may be considered in certain higher‐risk situations.
Methods
A comprehensive search of English language publications up to September 2023 was performed. The primary outcome was CMV relapse, defined as the recurrence of DNAemia or disease. Secondary outcomes included graft loss, mortality, and hematological toxicity. Meta‐analysis used the random‐effects model. The study protocol is registered in PROSPERO (no. CRD42022357028).
Results
Six retrospective comparative studies were included. A total of 520/727 (72%) of SOTR received SP with valganciclovir. The meta‐analysis did not demonstrate a significant difference in CMV relapse (odds ratio [OR] 1.15, 95% confidence interval [CI] 0.79–2.63). Heterogeneity between the studies was low ( I 2 = 0%, p = 0.57). SP was significantly associated with a reduction in mortality (OR 0.2, 95% CI 0.07–0.54) but not graft loss (OR 0.67, 0.17–2.63). There was no significant difference in CMV relapse among kidney‐specific SOTR (OR 1.38, 95% CI 0.65–2.96).
Conclusion
Evidence from six nonrandomized studies is limited and cannot support a recommendation for or against routine SP in SOTR treated for CMV infection. Awaiting prospective‐controlled trials, the decision about SP should depend on individualized risk‐profile assessments by experienced clinicians. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, Mater Misericordiae University Hospital, Dublin, Ireland.
- Department of Infectious Diseases, University Hospital Galway, Galway, Ireland.
- Department of Pathophysiology and Transplantation, University of Milano, Milan, Italy.
- Department of Infectious Diseases, ASST FBF SACCO Fatebenefratelli, Milan, Italy.
- Mayo Clinic Libraries, Mayo Clinic, Rochester, Minnesota, USA.
- Evidence-Based Practice Center, Mayo Clinic, Rochester, Minnesota, USA.
ORCID-Profile: David Moynan, Raymund R Razonable
Förderung
- Infectious Disease Society of Ireland
Zitieren
APA
Moynan, D., Higgins, E., Passerini, M., Prokop, L. J., Murad, M. H., & Razonable, R. R. (2024). Secondary anti‐viral prophylaxis in solid organ transplant recipients for the prevention of cytomegalovirus relapse: A systematic review and meta‐analysis. Transplant Infectious Disease. https://doi.org/10.1111/tid.14393
Vancouver
Moynan D, Higgins E, Passerini M, Prokop LJ, Murad MH, Razonable RR. Secondary anti‐viral prophylaxis in solid organ transplant recipients for the prevention of cytomegalovirus relapse: A systematic review and meta‐analysis. Transplant Infectious Disease. 2024. doi:10.1111/tid.14393
BibTeX
@article{Moynan2024,
author = {Moynan, David and Higgins, Eibhlin and Passerini, Matteo and Prokop, Larry J and Murad, Mohammad Hassan and Razonable, Raymund R},
title = {Secondary anti‐viral prophylaxis in solid organ transplant recipients for the prevention of cytomegalovirus relapse: A systematic review and meta‐analysis},
journal = {Transplant Infectious Disease},
year = {2024},
doi = {10.1111/tid.14393}
}
EUVIMED